Respiratory symptoms are ubiquitous and impair health-related quality of life in people with respiratory disease. This European Respiratory Society (ERS) task force aimed to provide recommendations for symptomatic treatment in people with serious respiratory illness.The ERS task force comprised 16 members, including representatives of people with serious respiratory illness and informal caregivers. Seven questions were formulated, six in the "Population, Intervention, Comparison, Outcome" (PICO) format, which were addressed with full systematic reviews and evidence assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE). One question was addressed narratively. An "evidence-to-decision" framework was used to formulate recommendations.To treat symptoms in people with serious respiratory illness, the task force suggests the use of graded exercise therapy (conditional recommendation, low certainty of evidence); and suggests the use of a multicomponent services, handheld fan and breathing techniques (conditional recommendations, very low certainty of evidence). The task force suggests not to use opioids (conditional recommendation, very low certainty of evidence); and suggests either administering or not administering supplemental oxygen therapy (conditional recommendation, low certainty of evidence). The task force suggests that needs assessment tools may be used as part of a comprehensive needs assessment, but do not replace patient centred care and shared decision making (conditional recommendation, low certainty of evidence). The low certainty of evidence, modest impact of interventions on patient-centred outcomes, and absence of effective strategies to ameliorate cough highlight the need for new approaches to reduce symptoms and enhance wellbeing for individuals who live with serious respiratory illness.
BACKGROUND: Human health is inextricably linked to planetary health. The desire to nurture and protect both concurrently requires the mitigation of healthcare-associated environmental harms and global initiatives that support sustainable lifestyles. Health leadership is important to bring adequate attention and action to address planetary health challenges. Health professionals are central to this endeavour, but the will and energy of a few will not be adequate to address this urgent challenge. STUDY: We present an appraisal of the current UK health professional standards, frameworks and curricula to identify content related to planetary health and environmental sustainability. RESULTS: No current UK health professional standard provides statements and competencies to guide practising and trainee health professionals to focus on and advance the sustainability agenda within their clinical practice and across wider healthcare systems. CONCLUSION: Update of health professional standards is needed to ensure that health professionals in every specialty are supported and encouraged to lead the implementation of environmentally sustainable practices within the health sector and advocate for planetary health.
The use of real-world evidence (RWE) studies, including pragmatic randomised controlled trials (RCTs; randomised RWE studies), to aid the development of treatment guidelines, is gradually becoming a mainstay within clinical practice. RWE is an integral part of patient-driven decision-making and offers important value to add complimentary evidence to traditional RCTs; these provide a more well-rounded view of the benefits to patient-reported outcomes and improve the external validity of a given treatment versus findings from traditional RCTs alone. Discussions in recent scientific workshops explored the importance of pragmatic RCTs in optimising guideline development and patient care in chronic obstructive pulmonary disease (COPD) and asthma. The Salford Lung Study in patients with COPD (NCT01551758) and asthma (NCT01706198) were the world's first prelicence pragmatic RCTs that compared novel investigational treatments with existing COPD and asthma treatments and, more recently (2021), RWE studies have been used by the American Thoracic Society and the US Food and Drug Administration to support the approval of an immunosuppressant drug in patients receiving lung transplants. This highlights the importance of RWE data in supporting clinical guideline development and emphasises the advantages for the use of pragmatic RCTs in guiding clinical practice.
Asthma , Pulmonary Disease, Chronic Obstructive , Asthma/drug therapy , Humans , Immunosuppressive Agents/therapeutic use , Pulmonary Disease, Chronic Obstructive/drug therapy , Randomized Controlled Trials as Topic , United States
Healthcare professionals should help patients to reach informed decisions about treatments in order to maximise benefits while minimising treatment burden https://bit.ly/2XRtRPK.
The full British Thoracic Society (BTS) guideline for the use of long-term macrolides in adults with respiratory disease is published in Thorax. The following is a summary of the recommendations and good practice points. The sections referred to in the summary refer to the full guideline. The appendices are available in the full guideline and online appendices are available on the BTS website. This is the first BTS guideline to use the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach as part of the process of guideline development and the guideline was used to pilot the new methodology.
Anti-Bacterial Agents/therapeutic use , Macrolides/therapeutic use , Respiratory Tract Diseases/drug therapy , Administration, Oral , Adult , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Humans , Macrolides/administration & dosage , Macrolides/adverse effects , Practice Guidelines as Topic , Societies, Medical , Time Factors , United Kingdom
Anti-Bacterial Agents/therapeutic use , Macrolides/therapeutic use , Respiratory Tract Diseases/drug therapy , Administration, Oral , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Asthma/drug therapy , Bronchiectasis/drug therapy , Bronchiolitis Obliterans/drug therapy , Cough/drug therapy , Drug Resistance, Bacterial , Humans , Macrolides/administration & dosage , Macrolides/adverse effects , Pneumonia/drug therapy , Pulmonary Disease, Chronic Obstructive/drug therapy , Time Factors
Parkinson's disease affects approximately 200 in every 100000 patients in London (Schrag et al, 2000). These individuals experience increased rates of emergency admissions to hospital secondary to falls, fractures, impaired mobility, infections, psychiatric disturbances and cardiovascular disease. The duration of their hospital stay is frequently prolonged compared to patients who do not have Parkinson's disease (Woodford and Walker, 2005). In addition, significant numbers of patients with Parkinson's disease are admitted for elective surgery.
